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Design and Synthesis of a Novel Magnetic
Resonance Imaging Contrast Agent for
Selective Sensing of Zinc Ion
Light-based microscope imaging techniques using
fluorescence sensor molecules sometimes suffer from
photobleaching and light scattering, but magnetic reso-
nance imaging (MRI) can allow imaging of intact, opaque
organisms in three dimensions without these problems
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The University of Tokyo [6]. While nuclear spins are excited with RF pulses, the
MRI apparatus typically imposes one or more magnetic7-3-1 Hongo
Bunkyo-ku field gradients upon a specimen. The MRI image is
based upon the NMR signal from the protons of water,Tokyo 113-0033
2 Drug Discovery Institute and the signal intensity depends upon the water concen-
tration and relaxation times (T1 and T2). Nowadays, thereNihon Schering K. K., 6-64
Nishimiyahara 2-chome Yodogawa-ku is great interest in MRI contrast agents, which can im-
prove the resolution of MR images [7]. Gadolinium (Gd3)Osaka 532-0004
3 Chemical Analysis Center complexes are widely used as contrast agents for MRI.
Most Gd3 complexes enhance the T1 (spin-lattice) andChiba University
Yayoi-cho T2 (spin-spin) relaxation rates of water protons by rapid
exchange of inner-sphere water molecules with bulkInage-ku
Chiba 263-8522 solvent. This enhancement is mediated, in part, by the
direct interaction of water molecules (inner sphere) with4 Presto
JST Corporation the unpaired electrons of the paramagnetic metal ion
Gd3 [8]. The longitudinal and transverse relaxivity val-Kawaguchi
Saitama ues R1 and R2 refer to the amount of increase in 1/T1
and 1/T2, respectively, per millimolar concentration ofJapan
agent (often given as per mM Gd). Many MRI contrast
agents for mapping of a particular tissue or organ have
been reported. When the agents are distributed to aSummary
particular tissue, that tissue shows a brighter appear-
ance in MRI [9, 10]. More recently, “smart” MRI contrastA series of new diethylenetriaminepentaacetic acid
(DTPA)-bisamide chelators has been prepared and agents which modulate the access of water to a chelated
gadolinium (Gd3) ion in the presence or absence of acharacterized for application as zinc sensors. We have
designed and synthesized (GdLa)2, which contains a specific trigger have been reported. For example, MRI
contrast agents which change the relaxation rate in theDTPA-bisamide moiety. The R1 relaxivity of (GdLa)2
solution decreased monotonically on the addition of presence of an enzyme activity or Ca2 or pH depen-
dently have been reported [11–15]. On the basis of theseZn2. Moreover, (GdLa)2 showed high selectivity for
Zn2 against Ca2 and Mg2. We also measured the UV- reports, we have already developed the Gd3 DTPA-
bisamide complex GdLc as a Zn2-sensitive MRI contrastvisible spectra and the coldspray ionization (CSI) MS
spectra and concluded that the 1-to-1 Zn2 complex agent (Figure 1). This complex was designed on the
basis that N,N,N’,N’-tetrakis(2-pyridylmethyl)ethylene-of (GdLa)2 is stable at higher concentrations of Zn2.
These complexes should provide the basis for creating diamine (TPEN) readily complexes with Zn2 but hardly
complexes with Ca2 and Mg2 [16, 17]. In this report,a superior Zn2-sensitive MRI contrast agent and are
excellent candidates for incorporation into sensors we designed and synthesized a novel Zn2-sensitive
MRI contrast agent: the Gd3 DTPA-bisamide complexdesigned for selective detection of Zn2 in biological
applications. (GdLa)2, which is a derivative of GdLc (Figure 1), and
measured the relaxation time T1 of aqueous solutions
of this compound.Introduction
Zinc (Zn2) is the second most abundant heavy metal
Results and Discussionion after iron in the human body. It is an essential compo-
nent of many enzymes, transcription factors [1, 2], and
The Gd3 DTPA-bisamide complex GdLc and the Gd3synaptic vesicles in excitatory nerve terminals [3] and
DTPA-amide-ethylester GdLd have been reported pre-is present in serum at a concentration of 12 M (total
viously (Figure 1) [18]. Solutions of GdLc showed a dose-Zn2) [4]. Recently, zinc has been reported to play impor-
dependent change of the water proton R1 relaxivity attant roles in regulating synaptic transmission and cell
pH 8.0 (0.1 M Tris buffer) in the presence of Zn2 and haddeath [5]. Therefore, imaging of chelatable Zn2 in the
high selectivity for Zn2 against Ca2 and Mg2 (Figure 2).extra- and intracellular environments or in tissues is of
The R1 decreased dose dependently between 0 and 1.0interest.
equivalents Zn2, reaching a minimum at 1.0 equivalent
Zn2, then R1 increased dose dependently between 1.05 Correspondence: tlomg@mol.f.u-tokyo.ac.jp (T.N.), kkikuchi@
mol.f.u-tokyo.ac.jp (K.K.) and 2.0 equivalents. This complex was designed on the
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Figure 2. R1 Relaxivity for Solutions of Gd3 DTPA-Bisamide Com-
plexes GdLc and (GdLa)2 upon Addition of Zn2, Ca2, or Mg2
R1 relaxivity (mM1 s1) of GdLc (A) or (GdLa)2 (B) was measured in
100 mM Tris buffer (pH 8.0) or 25 mM KMOPS buffer (pH 7.20),
respectively, at 25C. Cations were added as ZnCl2, CaCl2, or MgCl2
(1 equivalent to Gd3 DTPA-bisamide complexes, respectively).
[ZnGdLc]2, [ZnGdLc(H2O)]2, and [ZnGdLc(DMF)]2, re-
spectively. The mass spectrum of the 2:1 complex,
Zn2GdLc in H2O:2% DMF (4 mM) displayed five major
ion peaks at m/z  433, 457, 481, 663, and 917, cor-
responding to the cations [Zn2GdLc(ClO4)(DMF)]3,
[Zn2GdLc(ClO4)(DMF)2]3, [Zn2GdLc(ClO4)(DMF)3]3, [Zn2
GdLc(ClO4)2]2, and [(Zn2GdLc)2(ClO4)5]3, respectively.
These results support the above hypothesis on Zn2
chelation stoichiometry.
The behavior of the R1 relaxivity of GdLc solution is
Figure 1. Structure of Synthesized DTPA-Bisamide Chelators problematic because the response peaks above 1 equiv-
H3Lc and H3Ld were reported previously. H5La and H5Lb were newly alent of Zn2 are augmented and hence not monotonic.
synthesized. Briefly, for example, one cannot distinguish the R1 values
of solutions of GdLc containing 0.3 and 1.5 equivalents
of Zn2. Complex GdLc contains two amides, which have
weak chelating ability, and there is probably a stericbasis that N,N,N’,N’-tetrakis(2-pyridylmethyl)ethylene-
diamine (TPEN) readily complexes with Zn2 but hardly repulsion effect of the four pyridines. On the assumption
that this is so, we have designed and synthesized thecomplexes with Ca2 and Mg2 [16, 17], and reactions
between primary amines and DTPA-bisanhydride have Gd3 DTPA-bisamide complex (GdLa)2 as a Zn2-sensi-
tive MRI contrast agent (Figure 1). The reasoning behindbeen widely used in the synthesis of DTPA-bisamide
chelators [19]. On the other hand, the R1 relaxivity of the design of (GdLa)2 is as follows. The carboxylate
substituent chelates Zn2 strongly [23] and has a smallerGdLd solution in the presence of various concentrations
of Zn2 did not change with Zn2 concentration. We steric repulsion than pyridyl. So, we hoped to obtain a
monotonic change with this stronger chelator. Com-previously suggested that, upon addition of Zn2 be-
tween 0:1 and 1:1 Zn2/GdLc molar ratio, water mole- pound (GdLa)2 was synthesized according to the reac-
tion scheme shown in the Supplemental Data.cules bound directly to Gd3 of GdLc are displaced.
However, upon the addition of Zn2 between 1:1 and In characterizing (GdLa)2, we observed that the water
proton R1 relaxivity of (GdLa)2 solution had a Zn2 de-2:1 Zn2/GdLc molar ratio, Zn2 and GdLc form a 2:1
complex which bears the same number of water mole- pendence (Figure 4). The R1 decreased dose depen-
dently between 0 and 1.0 equivalents Zn2, reaching acules as GdLc only. This can be understood in terms of
the Zn2 coordination geometry, which is proposed to minimum at 1.0 equivalent Zn2, then R1 remained at a
plateau with further increase of Zn2. The R1 relaxivitybe as shown in Figure 3. Previously, this hypothesis was
supported by measuring the UV-visible spectra and the of (GdLa)2 solution decreased 30% when 1.0 equiva-
lent of Zn2 was added. To provide further insight intoR1 relaxivity of GdLd aqueous solution. In this report,
we also measured the coldspray ionization (CSI) mass this relaxation behavior, we examined the UV-visible
spectra of (GdLa)2 solution (300 M) at pH 7.20 (25 mMspectra of the 1:1 and 2:1 Zn2/GdLc complexes [20–22].
In the mass spectrum of the 1:1 complex, ZnGdLc in KMOPS buffer) in the presence of various concentra-
tions of Zn2 (Figure 5). The absorbance between 220H2O:2% DMF (1 mM), three major ion peaks, m/z 531,
540, and 568, were clearly observed. The ions m/z 531, and 300 nm changed linearly with increase of Zn2 con-
centration up to 1:1 Zn2/(GdLa)2 molar ratio, with iso-540, and 568 obtained from ZnGdLc were assigned as
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Figure 4. The Water Proton R1 Relaxivity of (GdLa)2 and (GdLb)2
The water proton R1 relaxivity of (GdLa)2 (closed triangle) and
(GdLb)2 (open triangle) (B) are measured in the presence of various
concentrations of Zn2: 0, 0.1, 0.3, 0.5, 1.0, 1.5, and 2.0 equivalents.
The R1 relaxivity of (GdLa)2 and (GdLb)2 were measured in 25 mM
KMOPS buffer (pH 7.20).
were clearly observed (data not shown). These ions, m/z
1033, 1102, and 1171, were assigned as [ZnGdLa-K],
[(ZnGdLa)2K(ClO4)-K2]2, and [ZnGdLaK(ClO4)-K], re-
spectively, supporting the idea that (GdLa)2 forms a 1:1
complex with Zn2. From the above data, the behavior
of the R1 relaxivity of (GdLa)2 solution can be rational-
ized as follows. When the Zn2/(GdLa)2 molar ratio is
between 0:1 and 1:1, Zn2 and (GdLa)2 form a 1:1 com-
plex. However, even when the Zn2/(GdLa)2 molar ratio
exceeds one, Zn2 and (GdLa)2 do not form a 2:1 com-
plex. We estimated that (GdLa)2 in the Zn2/(GdLa)2 1:1
complex has fewer water molecules binding directly to
Gd3 than (GdLa)2 in a Zn2-free solution, and this can
be understood in terms of the Zn2 coordination geome-
try, which is proposed to be as shown in Figure 3. The
reason why Zn2 and (GdLa)2do not form a 2:1 complex,
whereas Zn2 and GdLc do form a 2:1 complex, may be
as follows. Both (GdLa)2 and GdLc contain two amides,
Figure 3. Proposed Mechanism for the Decrement of R1 Relaxivity
of Gd3 DTPA-Bisamide Complex GdLc and (GdLa)2 in the Presence
of Zn2
Schematic representation of GdLc (A) and (GdLa)2 (B) for the pro-
posed conformational dependence of the structure in the presence
and absence of Zn2 is shown.
Figure 5. UV-Visible Spectra of (GdLa)2 in the Presence of Various
Concentrations of Zn2
UV-visible spectra of (GdLa)2 (300 M) in KMOPS (25 mM; pH 7.20)sbestic points at 254.5 and 272.5 nm, and remained at
in the presence of various concentrations of Zn2: 0 equivalent (open
a plateau with further increase of Zn2. Moreover, in the triangle), 0.5 equivalent (open square), 1.0 equivalent (open circle).
CSI mass spectrum of ZnGdLa in H2O/MeOH  1/1 (2.5 On the addition of Zn2 between 1.0 and 3.0 equivalents, the ab-
sorbance spectra remained at a plateau.mM), three major ion peaks, m/z 1033, 1102, and 1171,
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(25 mM KMOPS buffer) upon the addition of Zn2 (data
not shown). The absorbance spectrum of (GdLb)2 solu-
tion changed similarly to that of (GdLa)2 solution. The
absorbance between 220 and 300 nm changed linearly
with Zn2 concentration up to 1.16:1 Zn2/(GdLb)2 molar
ratio and remained at a plateau with further increase of
Zn2 concentration. It can be considered from these
results that (GdLb)2 and Zn2 form a complex, and the
water accessibility of the chelated Gd3 ion is not
changed by this complexation. We presume that the
Figure 6. T1-Weighted MR Images of (GdLa)2 Solutions in the Pres- difference between (GdLa)2 and (GdLb)2 is due to the
ence and Absence of Zn2 linkage between amide and tertiary amine. The ethylene
T1-weighted MRI contrast decreased as a result of Zn2 chelating bonding is shorter than the trimethylene bonding and
of (GdLa)2. Images of a solution of (GdLa)2 in the presence (right) thus may result in exclusion of water molecules from
and absence (left) of Zn2 [right: 0.25 mM (GdLa)2 and 0.25 mM
Gd3 upon Zn2 coordination. We also examined theZn2, left: 0.25 mM (GdLa)2] were obtained horizontally and are
effects of Ca2 and Mg2 on the R1 relaxivity of (GdLb)2displayed. Both samples were dissolved in distilled water in small
vials. aqueous solution. The R1 relaxivity of (GdLb)2 solution
at pH 7.20 (25 mM KMOPS) showed no change, even
when 1 equivalent of Ca2 or Mg2 was added.
which have weak chelating ability. However, the carbox- These characteristics of the complexes are favorable
ylate substituent, which La has, chelates Zn2 strongly for in vivo imaging of Zn2 concentration changes, for
and has a smaller steric repulsion than the pyridyl sub- example, by comparing signal intensity decay in a region
stituent of Lc. Therefore, it can be considered that the of interest with and without various stimuli, given that the
Zn2/(GdLa)2 1:1 complex is more stable than the Zn2/ clearance of the agent itself should remain unchanged.
GdLc 1:1 complex, and (GdLa)2 does not form a Zn2/
(GdLa)2 2:1 complex, in contrast to GdLc. Significance
In MR images of (GdLa)2 solution, the change in T1
generated by the addition of Zn2 [1 equivalent to Previously, we designed and synthesized the Gd3
(GdLa)2] could be visualized (Figure 6). Complex DTPA-bisamide complex GdLc as a Zn2-sensitive MRI
(GdLa)2 was dissolved in distilled water (0.25 mM). Zn2 contrast agent. For this agent, the decrease of the R1
[1 equivalent to (GdLa)2] was added to one sample but relaxivity upon addition of Zn2 can be understood in
terms of the Zn2 coordination geometry, which is pro-not to the other. The images displayed in Figure 6 reveal
posed to be as shown in Figure 3. This mechanismthat the T1-mediated contrast of (GdLa)2 was altered by
was supported by the UV-visible spectra, CSI masschelation of Zn2 with (GdLa)2.
spectra, and the experimental data of compound GdLd.For a Zn2-sensitive MRI contrast agent, high selectiv-
Here, we report the novel Gd3 DTPA-bisamide com-ity against Mg2 and Ca2 is crucial. Therefore, we exam-
plex (GdLa)2, which was designed on the basis of ourined the effects of Ca2, Mg2, Na, K, and H on the
work on GdLc. The R1 relaxivity of (GdLa)2 solutionR1 relaxivity of (GdLa)2 aqueous solution. There was no
decreased in the presence of Zn2 from 0:1 to 1:1 Zn2/large effect of H on the R1 relaxivity between pH 6 and
(GdLa)2 molar ratio and remained at a plateau upon8 in the absence of Zn2 (data not shown). The R1 curve
further addition of Zn2. Moreover, compound (GdLa)2exhibits no marked change and no pH dependence over
had high selectivity for Zn2 against Ca2 and Mg2.the pH range of 6–8. No effect of 100 mM Na or K on
We also synthesized the Gd3 DTPA-bisamide complexthe R1 relaxivity of (GdLa)2 solution was observed in the
(GdLb)2, which is an analog of (GdLa)2. The R1 relaxi-presence or absence of Zn2. The R1 relaxivity of (GdLa)2
vity of (GdLb)2 solution at pH 7.20 (25 mM KMOPS) insolution upon the addition of 1 equivalent of Ca2 or
the presence of various concentrations of Zn2 did notMg2 at pH 7.20 (25 mM KMOPS buffer) is illustrated in
change, and it also showed no change upon additionFigure 2, showing no change. Further, the R1 relaxivity
of Ca2or Mg2. Thus, these novel compounds, (GdLa)2of (GdLa)2 in 25 mM KMOPS buffer (pH 7.20) containing
and GdLc, are excellent candidates for incorporation5 mM Ca2 or 5 mM Mg2 showed no effects of Ca2 or
into sensors designed for selective detection of Zn2Mg2 in the presence or absence of Zn2 (data not
in biological applications. The molecule (GdLa)2 mayshown). Compound (GdLa)2 thus showed high selectiv-
also have the potential to form responsive luminescentity for Zn2 against Ca2 and Mg2.
lanthanide complexes (Eu, Tb) [24, 25].We also designed and synthesized the Gd3 DTPA-
bisamide complex (GdLb)2 (Figure 1). Compound
Experimental Procedures
(GdLb)2 was synthesized by using trimethylenediamine
as a starting material, instead of ethylenediamine for Materials
(GdLa)2. Compound (GdLb)2 was synthesized ac- DTPA-bisanhydride was purchased from Aldrich Chemical Co. Inc.,
USA. All other reagents were purchased from either Tokyo Kaseicording to the reaction scheme shown in Supplemental
Kogyo Co., Ltd., Japan, or Wako Pure Chemical Industries, Ltd.,Data. The water proton R1 relaxivity of (GdLb)2 solution
Japan. All solvents were used after distillation.at pH 7.20 (25 mM KMOPS buffer) in the presence of
various concentrations of Zn2 did not change with Zn2 Instruments
concentration (Figure 4). We also measured the UV- 1H- and 13C-NMR spectra were recorded on a JEOL JNM-LA300.
Mass spectra were measured with a JEOL JMS-DX 300 mass spec-visible spectra of (GdLb)2 solution (300 M) at pH 7.20
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trometer (EI) or a JEOL JMS-700T mass spectrometer (FAB). UV- A growing appreciation for the roles of zinc. Science 271, 1081–
1085.visible spectra were obtained on a Shimadzu UV-1600. HPLC purifi-
cation was performed on a reverse-phase column (GL Sciences, 3. Frederickson, C.J. (1989). Neurobiology of zinc and zinc-con-
taining neurons. Int. Rev. Neurobiol. 31, 145–238.Inertsil Prep-ODS 30 mm  250 mm) fitted on a Jasco PU-1587
System. MR images were obtained on a Varian INOVA200 (4.7 T): 4. Parker, M.M., Humoller, F.L., and Mahler, D.J. (1967). Determi-
nation of copper and zinc in biological material. Clin. Chem. 13,Spin Echo Tr/Te  300/9.4 ms, Matrix 256*128, NEX  4, FOV 
6*6 cm, slice thickness  2 mm. 40–48.
5. Choi, D.W., and Koh, J.Y. (1998). Zinc and brain injury. Annu.
Rev. Neurosci. 21, 347–375.Preparation of Solutions
6. Caravan, P., Ellison, J.J., McMurry, T.J., and Lauffer, R.B. (1999).The gadolinium complexes K2(GdLa) and K2(GdLb) were prepared by
Gadolinium(III) chelates as MRI contrast agents: Structure, dy-a modification of the literature procedures [26, 27]. Ligand H5La or
namics, and applications. Chem. Rev. 99, 2293–2352.H5Lb was dissolved in distilled water. To this solution, 1 N KOH
7. Degani, H., Gusis, V., Weinstein, D., Fields, S., and Strano, S.was added until the pH reached 7.0. An equal molar amount of an
(1997). Mapping pathophysiological features of breast tumorsaqueous solution of GdCl3-6H2O was then added slowly, while a pH
by MRI at high spatial resolution. Nat. Med. 3, 780–782.of 7 was maintained by further addition of 1 N KOH. The solution
8. Botta, M. (2000). Second coordination sphere water moleculeswas kept at room temperature under vigorous stirring for 1 hr until
and relaxivity of gadolinium(III) complexes: Implications for MRIthe pH was stabilized. The compound was then purified by precipita-
contrast agents. Eur. J. Inorg. Chem. 2000, 399–407.tion by the addition of acetone. K2(GdLa): a colorless solid; HRMS
9. Schmitt-Willich, H., Brehm, M., Ewers, C.L.J., Michl, G., Mu¨ller-(FAB) Calcd for (M-K2H) m/z 969.2150, found 969.2177. HPLC
Fahrnow, A., Petrov, O., Platzek, J., Radu¨chel, B., and Su¨lzle,analysis: retention time, 10.5 min (purity, 98.4% integrated intensity);
D. (1999). Synthesis and physicochemical characterization of aInertsil ODS-3 4.6 mm  250 mm (Gl Sciences); eluent, a 20 min
new gadolinium chelate: The liver-specific magnetic resonancelinear gradient, from 0% to 80% solvent B (solvent A, 0.1 M
imaging contrast agent Gd-EOB-DTPA. Inorg. Chem. 38, 1134–Et3N-AcOH; solvent B, acetonitrile-H2O [80:20]); flow rate, 1.0 ml;
1144.UV, 254 nm. K2(GdLb): a colorless solid; HRMS (FAB) Calcd for
10. Gehl, H.B., Bourne, M., Grazioli, L., Mo¨ller, A., and Lodemann,(M-2K3H) m/z 959.2907, Found 959.2847. HPLC analysis: reten-
K.P. (2001). Off-site evaluation of liver lesion detection by Gd-tion time, 10.7 min (purity, 98.3% integrated intensity); Inertsil ODS-3
BOPTA-enhanced MR imaging. Eur. Radiol. 11, 187–192.4.6 mm  250 mm (Gl Sciences); eluent, a 20 min linear gradient,
11. Moats, R.A., Fraser, S.E., and Meade, T.J. (1997). A “smart”from 0% to 80% solvent B (solvent A, 0.1 M Et3N-AcOH; solvent B,
magnetic resonance imaging agent that reports on specific en-acetonitrile-H2O [80:20]); flow rate, 1.0 ml; UV, 254 nm. All samples
zymatic activity. Angew. Chem. Int. Ed. Engl. 36, 726–728.were assessed for the absence of free gadolinium ions using xylenol
12. Louie, A.Y., Hu¨ber, M.M., Ahrens, E.T., Rothba¨cher, U., Moats,orange as the indicator. The solutions of the gadolinium complex
R., Jacobs, R.E., Fraser, S.E., and Meade, T.J. (2000). In vivofor the relaxation time measurement were prepared by dissolving
visualization of gene expression using magnetic resonance im-the above solid compound in a buffer solution.
aging. Nat. Biotech. 18, 321–325.
13. Li, W.H., Fraser, S.E., and Meade, T.J. (1999). A calcium-sensi-Relaxation Time Measurement
tive magnetic resonance imaging contrast agent. J. Am. Chem.The relaxation time T1 of aqueous solutions of the Gd3 complex
Soc. 121, 1413–1414.(GdLa)2 or (GdLb)2 was measured in KMOPS buffer (25 mM; pH
14. Zhang, S.R., Wu, K.C., and Sherry, A.D. (1999). A novel pH-7.20) by using the standard inversion-recovery procedure (JEOL
sensitive MRI contrast agent. Angew. Chem. Int. Ed. 38, 3192–JNM-LA300, 25C). The R1 relaxivity of these compounds was deter-
3194.mined from the slope of the plot of 1/T1 versus [(GdLa)2] or [(GdLb)2]
15. Mikawa, M., Miwa, N., Braautigam, M., Akaike, T., and Maru-(0.4, 0.6, 0.8, 1.0 mM). The buffered Gd3 complex [(GdLa)2 or
yama, A. (2000). Gd3-loaded polyion complex for pH depiction(GdLb)2] solution was allowed to equilibrate for at least 10 min after
with magnetic resonance imaging. J. Biomed. Mater. Res. 49,the addition of ZnCl2, CaCl2, or MgCl2 aqueous stock solution.
390–395.
16. Hirano, T., Kikuchi, K., Urano, Y., Higuchi, T., and Nagano, T.
CSI Mass Measurement
(2000). Highly zinc-selective fluorescent sensor molecules suit-
CSI mass spectra were measured with a JEOL JMS-700 mass spec-
able for biological applications. J. Am. Chem. Soc. 122, 12399–
trometer. The desolvating plate temperature was 23C. In CSI mass
12400.
measurement, Zn(ClO4)2 aqueous solution was used as Zn2 stock 17. Cuajungco, M.P., and Lees, G.J. (1998). Diverse effects of metal
solution. In the mass spectrum measurement, Zn2 and Gd3 com-
chelating agents on the neuronal cytotoxicity of zinc in the
plexes were mixed in H2O:2% DMF (1 mM), H2O:2% DMF (4 mM), and hippocampus. Brain Res. 799, 97–107.
H2O/MeOH  1/1 (2.5 mM), corresponding to solutions of ZnGdLc, 18. Hanaoka, K., Kikuchi, K., Urano, Y., and Nagano, T. (2001). Se-
Zn2GdLc, and ZnGdLa, respectively. lective sensing of zinc ions with a novel magnetic resonance
imaging contrast agent. J. Chem. Soc.-Perkin Trans. 2, 1840–
Supplemental Data 1843.
Experimental details for the synthesis of H5La and H5Lb. CSI mass 19. Bligh, S.W.A., Chowdhury, A.H.M.S., Kennedy, D., Luchinat, C.,
spectra for 1:1 complex; ZnGdLc and 2:1 complex; Zn2GdLc. Please and Parigi, G. (1999). Non-ionic bulky Gd(III) DTPA-bisamide
write to chembiol@cell.com for a PDF. complexes as potential contrast agents for magnetic resonance
imaging. Magn. Reson. Med. 41, 767–773.
Acknowledgments 20. Sakamoto, S., Fujita, M., Kim, K., and Yamaguchi, K. (2000).
Characterization of self-assembling nano-sized structures by
We thank Nihon Schering K.K. for advice and for measuring MR means of coldspray ionization mass spectrometry. Tetrahedron
images. 56, 955–964.
21. Sakamoto, S., Yoshizawa, M., Kusukawa, T., Fujita, M., and
Received: April 5, 2002 Yamaguchi, K. (2001). Characterization of encapsulating supra-
Revised: July 8, 2002 molecules by using CSI-MS with ionization-promoting reagents.
Accepted: August 13, 2002 Org. Lett. 3, 1601–1604.
22. Yamanoi, Y., Sakamoto, Y., Kusukawa, T., Fujita, M., Sakamoto,
S., and Yamaguchi, K. (2001). Dynamic assembly of coordina-References
tion boxes from (en)Pd(II) unit and a rectangular panel-like li-
gand: NMR, CSI-MS, and X-ray studies. J. Am. Chem. Soc. 123,1. Vallee, B.L., and Falchuk, K.H. (1993). The biochemical basis of
980–981.zinc physiology. Physiol. Rev. 73, 79–118.
2. Berg, J.M., and Shi, Y.G. (1996). The galvanization of biology: 23. Sille´n, L.G., and Martell, A.E. (1964). Stability Constants of Metal-
Chemistry & Biology
1032
ion Complexes, Special Publication No. 17. (London: The Chem-
ical Society, Burlington House).
24. Aime, S., Barge, A., Botta, M., Howard, J.A.K., Kataky, R., Lowe,
M.P., Moloney, J.M., Parker, D., and de Sousa, A.S. (1999).
Dependence of the relaxivity and luminescence of gadolinium
and europium amino-acid complexes on hydrogencarbonate
and pH. Chem. Commun. 11, 1047–1048.
25. Lowe, M.P., and Parker, D. (2000). Controllable pH modulation
of lanthanide luminescence by intramolecular switching of the
hydration state. Chem. Commun. 8, 707–708.
26. Hardcastle, K.I., Botta, M., Fasano, M., and Digilio, G. (2000).
Experimental evidence for a second coordination sphere water
molecule in the hydration structure of YbDTPA - Insights for a
re-assessment of the relaxivity data of GdDTPA. Eur. J. Inorg.
Chem. 5, 971–977.
27. Anelli, P.L., Bertini, I., Fragai, M., Lattuada, L., Luchinat, C., and
Parigi, G. (2000). Sulfonamide-functionalized gadolinium DTPA
complexes as possible contrast agents for MRI: A relaxometric
investigation. Eur. J. Inorg. Chem. 4, 625–630.
